Table 2.
Study parameters upon stratification by eosinophil count.
Parameter | Eosinopenia n = 99 (36%) |
Normal eosinophil count n = 176 (64%) |
P-value |
---|---|---|---|
Age (years), mean (SD) | 70.24 (9.48) | 68.96 (9.64) | 0.29 |
Male, n (%) | 51 (51.51) | 101 (57.39) | 0.42 |
Active smoker, n (%) | 58 (58.59) | 44 (25) | < 0.0001 |
Length of hospitalizationc (days), median (IQR) | 8 (6–12.75) | 7 (5–10) | 0.004 |
Character of ECOPD | |||
Infectious, n (%) | 60 (60.61) | 86 (48.86) | 0.06 |
CRP (mg/l), median (IQR) | 15.53 (6.79–30.29) | 10.14 (2.79–23.41) | 0.07 |
WBC (× 103/μl), median (IQR) | 11.4 (8.17–13.2) | 8.9 (7.67–11.57) | 0.0007 |
Lymphocytes (× 103/μl), median (IQR) | 1.1 (0.7–1.8) | 1.8 (1.2–2.4) | < 0.0001 |
Neutrophils (× 103/μl), median (IQR) | 9.2 (6.1–11.55) | 6.1 (4.6–7.95) | < 0.0001 |
NLR, median (IQR) | 8.44 (4.37–12.72) | 2.26 (0.14–3.69) | < 0.0001 |
Hemoglobin (g/dl), median (IQR) | 13.9 (12.6–15.15) | 14.2 (13–15.13) | 0.29 |
pH, median (IQR) | 7.42 (7.39–7.46) | 7.42 (7.39–7.45) | 0.65 |
pCO2 (mmHg), median (IQR) | 38.9 (35.2–47.65) | 38.7 (35.3–44.5) | 0.86 |
pO2 (mmHg), median (IQR) | 63.9 (54.5–73.5) | 63 (55.65–71) | 0.96 |
SaO2 (%), median (IQR) | 92.7 (88.05–95.3) | 92.4 (89.65–94.8) | 0.86 |
HCO3− (mEq/l), median (IQR) | 26 (23.93–28.68) | 24.95 (23.2–27.98) | 0.1 |
BE (mEq/l), median (IQR) | 1.5 (− 0.08 to 3.73) | 0.75 (− 0.7 to 2.48) | 0.04 |
Comorbidities | |||
Ischemic heart disease, n (%) | 37 (37.37) | 49 (27.84) | 0.1 |
AFa, n (%) | 20 (20.2) | 11 (6.25) | 0.0004 |
Arrhythmia other than AFb, n (%) | 2 (2.02) | 6 (3.41) | 0.72 |
Congestive heart failure, n (%) | 45 (45.45) | 71 (40.34) | 0.41 |
Arterial hypertension, n (%) | 57 (57.58) | 122 (69.32) | 0.05 |
Type 2 diabetes, n (%) | 26 (26.26) | 40 (22.73) | 0.51 |
Others, n (%) | 83 (83.84) | 69 (39.2) | 0.0003 |
AF atrial fibrillation, CRP c-reactive protein, IQR interquartile range, WBC white blood count.
aFirst detected in the admission, paroxysmal, persistent or permanent.
bIn the admission or in the past medical history.
cAmong survivors.